

**Company Number 622227**

**PG Morris Oncology Limited**  
**Unaudited Abridged Financial Statements**  
**for the year ended 31st March 2025**

**PG Morris Oncology Limited**

**Company Information**

<b>Directors</b>	Patrick Morris Carla Fazio
<b>Secretary</b>	Patrick Morris
<b>Company Number</b>	622227
<b>Registered Office</b>	Beaumont Private Clinic Beaumont Road Dublin 9
<b>Business Address</b>	Beaumont Private Clinic Beaumont Road Dublin 9
<b>Bankers</b>	Bank of Ireland University Branch Montrose Dublin 4

## PG Morris Oncology Limited

<b>Contents</b>	<b>Page</b>
Statement of Directors' Responsibilities - Audit Exempt	1
Directors' Declaration on Unaudited Financial Statements	2
Abridged Balance Sheet	3
Notes to the Financial Statements	4 - 8

**PG Morris Oncology Limited**

**Statement of Directors' Responsibilities and Declaration on Unaudited Financial Statements  
for the year ended 31st March 2025**


The directors are responsible for preparing the Directors' Report and the financial statements in accordance with Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial period. Under the law, the directors have elected to prepare the financial statements in accordance with Irish Generally Accepted Accounting Practice (FRS 102) giving a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014. In preparing these financial statements the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy and enable them to ensure that the financial statements and directors' report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On behalf of the board of directors



**Patrick Morris**  
Director



**Carla Fazio**  
Director

**Date: 22nd December 2025**

**PG Morris Oncology Limited**

**Directors' Declaration on Unaudited Financial Statements  
for the year ended 31st March 2025**

In relation to the financial statements as set out on pages 3 to 8.

- The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.
- The directors confirm that they have made available the company's accounting records and provided all the information necessary for the compilation of the financial statements.
- The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the year ended 31st March 2025.

**On behalf of the Board**

  
\_\_\_\_\_  
Patrick Morris

)

  
\_\_\_\_\_  
Carla Fazio

) Directors

)

**Date: 22nd December 2025**

**PG Morris Oncology Limited**


**Unaudited Abridged Balance Sheet  
as at 31st March 2025**

	Notes	2025		2024	
		€	€	€	€
<b>Fixed Assets</b>					
Tangible assets	6		-		27
<b>Current Assets</b>					
Debtors		72,856		76,450	
Cash at bank and in hand		298,294		232,709	
		<u>371,150</u>		<u>309,159</u>	
<b>Creditors: amounts falling due within one year</b>	7	<u>(36,702)</u>		<u>(33,663)</u>	
<b>Net Current assets</b>			<u>334,448</u>		<u>275,496</u>
<b>Total Assets Less Current Liabilities</b>			<u>334,448</u>		<u>275,523</u>
<b>Capital and Reserves</b>					
Called up share capital	8		100		100
Profit and loss account			<u>334,348</u>		<u>275,423</u>
<b>Shareholders' Funds</b>			<u>334,448</u>		<u>275,523</u>

We, as directors of PG Morris Oncology Limited, state that:

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in Section 358 are complied with,
- (c) no notice under subsection (1) of section 334 has in accordance with subsection (2) of that section been served on the company,
- (d) we acknowledge the company's obligation under the Companies Act 2014, to keep adequate accounting records and prepare Financial Statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of Companies Act 2014 relating to Financial Statements so far as they are applicable to the company and
- (e) the company has relied on the specified exemption contained in Section 352 Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with Section 353 Companies Act 2014.

The financial statements were approved and authorised for issue by the Board of Directors on 22 December 2025 and signed on its behalf by

  
 \_\_\_\_\_  
**Patrick Morris**  
 Director

  
 \_\_\_\_\_  
**Carla Fazio**  
 Director

## PG Morris Oncology Limited

### Notes to the Unaudited Abridged Financial Statements for the year ended 31 March 2025

#### 1. General Information

The financial statements comprising the Profit and Loss Account, the Balance Sheet and the related notes constitute the individual financial statements of PG Morris Oncology Ltd for the year ended 31st March 2025.

PG Morris Oncology Ltd is a private company limited by shares, incorporated and registered in the Republic of Ireland (Company Registered Number 622227). The Registered Office is Beaumont Private Clinic, Beaumont Road, Dublin 9. The nature of the company's operations and its principal activities are set out in the Directors' Report.

The unaudited financial statements have been prepared in accordance with FRS 102, applying section 1A of that Standard.

#### 1.1. Currency

The financial statements have been presented in the Euro currency (€) which is also the functional currency of the company.

#### 2. Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### 2.1. Basis of preparation

The unaudited financial statements have been prepared on the going concern basis, under the historical cost convention, (as modified by the revaluation of certain tangible fixed assets) and comply with the financial reporting standards of the Financial Reporting Council, as promulgated by Chartered Accountants Ireland and the Companies Act 2014 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland, applying Section 1A of that Standard.

#### 2.2. Cash Flow Statement

The company has taken advantage of the exemption in FRS 102, applying Section 1A of that Standard from the requirement to produce a cashflow statement because it is a small company.

#### 2.3. Turnover

Turnover represents the total invoice value of fees raised during the year. The provision of medical services, such as are offered by PG Morris Oncology Limited, is exempt from VAT. Turnover is recognised when the medical consulting services offered by the company have been provided to the clients.

#### 2.4 Going Concern

The accounts are prepared on a going concern basis which assumes that the company will continue in existence for the foreseeable future with no intention to liquidate or significantly curtail its activities in the next 12 months. The directors are satisfied that it is appropriate for the financial statements to be prepared on a going concern basis.

**PG Morris Oncology Limited**

**Notes to the Unaudited Abridged Financial Statements  
for the year ended 31 March 2025**

..... continued

**2.5. Taxation**

The charge for taxation is based on the profit for the year and is calculated with reference to the tax rates applying at the financial year end date in the jurisdiction where the tax is applied.

Deferred taxation is accounted for in respect of all timing differences between profit as computed for taxation purposes and profit as stated in the financial statements to the extent that such differences are expected to reverse in the foreseeable future.

**2.6. Tangible fixed assets and depreciation**

Tangible fixed assets are initially recorded at historic cost less accumulated depreciation and impairment losses. This includes legal fees, stamp duty and other non-refundable purchase taxes, and also any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management, which can include the costs of site preparation, initial delivery and handling, installation and assembly, and testing of functionality.

Depreciation is provided at rates calculated to write off the cost less residual value of each asset over its expected useful life, as follows:

Computer equipment                      -     35% Straight Line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying cost of the asset, and is credited or charged to the profit and loss account.

**2.7. Cash and cash equivalents**

Cash consists of cash on hand and demand deposits. Cash equivalents consist of short term highly liquid investments that are readily convertible to known amounts of cash that are subject to an insignificant risk of change in value.

**2.8. Trade and other debtors**

Trade and other debtors are recognised initially at transaction price unless a financing arrangement exists in which case they are measured at the present value of future receipts discounted at a market rate. Subsequently these are measured at amortised cost less any provision for impairment. A provision for impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of receivables. The amount of the provision is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the effective interest rate. All movements in the level of the provision required are recognised in the profit and loss.

**2.9. Creditors and accruals**

Creditors and accruals are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

**2.10. Share Capital**

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

PG Morris Oncology Limited

Notes to the Unaudited Abridged Financial Statements  
for the year ended 31 March 2025

..... continued

**3. Critical Accounting Judgements and Estimates**

The preparation of these financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses.

Judgements and estimates are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

*(a) Establishing useful economic lives for depreciation purposes of tangible fixed assets*

Long-lived assets, consisting primarily of Tangible fixed assets, are subject to an annual depreciation charge, which depends primarily on the estimated useful economic lives of each type of asset and estimates of residual values. The directors regularly review these asset useful economic lives and change them as necessary to reflect current thinking on remaining lives in light of prospective economic utilisation and physical condition of the assets concerned. Changes in asset useful lives can have a significant impact on depreciation and amortisation charges for the period. Detail of the useful economic lives is included in the accounting policies.

*(b) Providing for doubtful debts*

The company makes an estimate of the recoverable value of trade and other debtors. The company uses estimates based on historical experience in determining the level of debts, which the company believes, will not be collected. These estimates are based on probability of default after calculating the company's risk points. Any significant reduction in the level of customers that default on payments or other significant improvements that resulted in a reduction in the level of bad debt provision would have a positive impact on the operating results.

**4. Pensions**

The pension costs charged in the financial statements represent the contribution payable by the company during the year.

The regular cost of providing retirement pensions and related benefits is charged to the profit and loss account over the employees' service lives on the basis of a constant percentage of earnings.

**5. Directors' emoluments**

	2025	2024
	€	€
Remuneration and other emoluments	103,000	103,000
Pension contributions	82,800	75,900
	<u>185,800</u>	<u>178,900</u>

**PG Morris Oncology Limited**

**Notes to the Unaudited Abridged Financial Statements  
for the year ended 31 March 2025**

..... continued

<b>6. Fixed assets</b>	<b>Tangible fixed assets €</b>	
<b>Cost</b>		
At	2,238	
At 31 March 2025	<u>2,238</u>	
<b>Depreciation</b>		
At	2,211	
Charge for year	27	
At 31 March 2025	<u>2,238</u>	
<b>Net book values</b>		
At 31 March 2024	<u><u>27</u></u>	
<b>7. Creditors: amounts falling due within one year</b>	<b>2025 €</b>	<b>2024 €</b>
Creditors include the following:		
Taxation	<u>19,279</u>	<u>23,478</u>
<b>Included in Taxation:</b>		
Corporation Tax	16,155	20,191
PAYE	2,772	2,906
PRSI	352	381
	<u>19,279</u>	<u>23,478</u>
<b>8. Share capital</b>	<b>2025 €</b>	<b>2024 €</b>
<b>Authorised equity</b>		
1,000,000 Ordinary shares of €1 each	<u>1,000,000</u>	<u>1,000,000</u>
<b>Allotted, called up and fully paid equity</b>		
100 Ordinary shares of €1 each	<u>100</u>	<u>100</u>

**PG Morris Oncology Limited**

**Notes to the Unaudited Abridged Financial Statements  
for the year ended 31 March 2025**

..... continued

**9. Transactions with directors**

**Directors and their interests**

The directors who served during the year and their interests in the company are as stated below:

	<b>Ordinary shares</b>	
	<b>2025</b>	<b>2024</b>
Patrick Morris	50	50
Carla Fazio	50	50
	<u>50</u>	<u>50</u>

**10. Approval of financial statements**

The board of directors approved these financial statements for issue on 22nd December 2025.